Señales en vivo de NBIX | Maximiza tus Ganancias con Getagraph.com

VENDER 2610 min ago

@ $140.54

Emitido: 3 may 2024 @ 11:55

Retorno: 0.12%

Señal anterior: may 1 - 15:54

Señal anterior: Comprar

Retorno: -1.41 %

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 16:00):

Stats
Volumen de hoy	604 739
Volumen promedio	908 056
Capitalización de mercado	14.00B
EPS	$1.440 ( 2024-05-01 )
Próxima fecha de ganancias	( $1.010 ) 2024-05-22
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	38.34
ATR14	$2.30 (1.63%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-15	Benevich Eric	Buy	12 587	Common Stock
2024-04-15	Benevich Eric	Buy	7 231	Common Stock
2024-04-15	Benevich Eric	Sell	12 587	Common Stock
2024-04-15	Benevich Eric	Sell	7 231	Non-Qualified Stock Option
2024-04-15	Benevich Eric	Sell	12 587	Non-Qualified Stock Option

INSIDER POWER
21.03
Last 100 transactions
Buy: 793 011 \| Sell: 504 436

Volumen Correlación

Largo: -0.05 (neutral)

Corto: 0.42 (neutral)

Signal:(52) Neutral

Neurocrine Biosciences Correlación

10 Correlaciones Más Positivas
OPHC	0.817
HMST	0.802

10 Correlaciones Más Negativas
RMRM	-0.911
TANH	-0.832
GNUS	-0.807

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Neurocrine Biosciences Correlación - Moneda/Commodity

0.11
( neutral )

0.31
( neutral )

0.00
( neutral )

0.11
( neutral )

-0.01
( neutral )

Neurocrine Biosciences Finanzas

Annual	2023
Ingresos:	$1.89B
Beneficio Bruto:	$1.85B (97.90 %)
EPS:	$2.56

FY	2023
Ingresos:	$1.89B
Beneficio Bruto:	$1.85B (97.90 %)
EPS:	$2.56

FY	2022
Ingresos:	$1.49B
Beneficio Bruto:	$1.47B (98.44 %)
EPS:	$1.610

FY	2021
Ingresos:	$1.13B
Beneficio Bruto:	$1.12B (98.74 %)
EPS:	$0.940

Financial Reports:

No articles found.

Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.